Related Experiment Video
Updated: May 8, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
A 50-year journey to cure childhood acute lymphoblastic leukemia
Ching-Hon Pui1, William E Evans
1Departments of Oncology and Pharmaceutical Sciences, St. Jude Children's Research Hospital. ching-hon.pui@stjude.org
Insights
Researchers reflect on 50 years of progress toward curing childhood acute lymphoblastic leukemia (ALL), highlighting key achievements and future directions in pediatric cancer research.
Area of Science:
- Hematology
- Pediatric Oncology
- Cancer Research
Background:
- The 50th anniversary of Seminars in Hematology and St. Jude Children's Research Hospital marks significant progress in treating childhood acute lymphoblastic leukemia (ALL).
- Historical review of advancements in understanding and treating pediatric ALL.
- The journey from limited treatment options to achieving cures.
Purpose of the Study:
- To commemorate 50 years of research milestones in curing childhood ALL.
- To identify key institutions, study groups, and individuals instrumental in achieving cures.
- To discuss contemporary advances and future research directions in pediatric leukemia.
Main Methods:
- Historical review and retrospective analysis of research contributions.
- Identification of pivotal studies, experimental tools, and therapeutic strategies.
- Discussion of emerging genomic and immunologic-based treatment modalities.
Main Results:
- Significant progress has been made in the cure rates for childhood ALL over the past 50 years.
- Advancements were driven by novel ideas and improved experimental tools for assessing leukemic blasts.
- The development of effective therapeutic strategies has transformed outcomes for affected children.
Conclusions:
- The cure of childhood ALL is a testament to audacious research and a focus on cure over palliation.
- Future research must integrate novel genomic and immunologic approaches with established chemotherapy to further improve outcomes.
- Continued innovation is essential to overcome challenges in treating catastrophic pediatric diseases like ALL.
Abstract:
The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children's Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:56Treatment Resistant Cancers